Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.
about
Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasomeMolecular targets of aspirin and cancer prevention.Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic InjuryAlleviating Promotion of Inflammation and Cancer Induced by Nonsteroidal Anti-Inflammatory DrugsAspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study.Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.Aspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential role in chemoprevention.Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.Association study of two inflammation-related polymorphisms with susceptibility to hepatocellular carcinoma: a meta-analysis.Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP studyAssociation between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study.Chemopreventive strategies in hepatocellular carcinomaStatin use and risk of primary liver cancer in the Clinical Practice Research Datalink.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.Circulating Tumor Cell Analyses in Patients With Esophageal Squamous Cell Carcinoma Using Epithelial Marker-Dependent and -Independent ApproachesA novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma.NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project.Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation.Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink.LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathwayCyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention.Dietary fatty acids and risk of hepatocellular carcinoma in the Singapore Chinese health study.AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis.Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection.Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.Nonselective inhibition of prostaglandin-endoperoxide synthases by naproxen ameliorates acute or chronic liver injury in animals.Spontaneous regression of hepatocellular carcinoma in a Caucasian male patient: A case report and review of the literatureChronic hepatitis B: role of anti-platelet therapy in inflammation control.Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.The cheating liver: imaging of focal steatosis and fatty sparing.Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma.Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.Adjuvant Medications That Improve Survival after Locoregional Therapy.Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection.Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation.
P2860
Q27319760-E3C62848-E2D3-44D7-B921-63522FB05817Q27687847-C7791E10-C3AC-43DC-A5FB-37E51527913CQ28072762-C9FC20B6-265B-4E79-9877-A4F4241F6BC9Q30234292-C3967BCB-2D46-473E-B656-A26F218A49EAQ33728292-CDD51D34-9E85-4F77-9B61-A3CF3835A771Q33946524-E60BFF80-03EF-48F8-B846-E6EAB4CCF1F5Q34351552-7193DDC3-83C8-4A17-8A57-38048F35225DQ34491262-F4DC7A5A-B233-4FA7-81F9-EC728D4E7428Q34511085-4A4317A1-6D6A-445F-AA17-C24D148E7444Q34537824-C9502C27-4C4F-41B8-BE8F-DA34DA539B8AQ34797536-4F73BB0F-9AF5-4140-844E-B1DFE3FCDDF4Q35071202-629A6876-1B79-4D00-98DD-44D8F9A46046Q35101365-D08B6CB8-BAB3-4EF0-8E5A-2F88AAA9441DQ35152907-F59B89E5-5EF0-4442-B02C-A22390EAC983Q35619104-FB8571CA-F0DF-459D-B17B-B81823165ED8Q36017220-21C278B3-3F96-444F-8519-3CB72B190258Q36255936-5BFC664C-F5CE-4713-A8C6-F326B768F1A1Q36291996-A7849D98-D796-4CEE-9F5F-3E3079D2EA88Q36439797-029D4926-6E96-4476-9E11-D24BA6F53A80Q36461735-047E117F-56C5-45F0-B926-4DAF7B6416DEQ36603129-FB38904A-E8B1-4A19-93F7-FACAC2FDD329Q36609598-264FCC38-4AD6-4485-BB9B-51C3B52ACA8AQ36619028-42D5519E-1C60-405D-9C5B-CFA40E9D88BAQ36693257-037355B6-F8BB-47F0-B2B0-2757FD398693Q36777552-3CEE7409-30AB-45BF-ADDC-016E494768F2Q37086032-979173BE-9026-475D-B4A8-9661AF6A3F92Q37298338-4BAA6D39-7A53-464D-B5A8-642B73849068Q37408920-3689985C-1E7C-4126-BDFD-D6FFC30CA34EQ37432586-08E741E2-63BA-4EDE-959E-F5981B8A46F7Q37584843-1C2AF4A0-612E-444F-A65E-22B6B8B368A6Q37621796-7376553D-6E95-4D43-A9A2-5BF439942169Q37701757-66CF88BD-92B6-402C-A0EF-AE04ACCC83C3Q38314202-E8E3327D-80B9-4F9A-9A33-A32139D71E57Q38724288-E722908E-2FE9-4A60-85E7-9C0C45D4EC53Q38793475-0D24479B-6120-494B-AD68-A1ACD9E0E3BCQ38923529-420FC5B0-B85F-4778-B9FF-415E0B41A86DQ39143287-77320AEB-A729-4C44-B0D1-D428D9F9EEAEQ39319921-7F10BAAA-E4A1-4A8A-BF52-51497CD5EDB1Q39473320-3F2E93D0-AD9E-4B17-B927-5C05AFD59540Q40044969-7C494BDC-174C-4EA1-986A-C8B70E1659EC
P2860
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Nonsteroidal anti-inflammatory ...... and hepatocellular carcinoma.
@ast
Nonsteroidal anti-inflammatory ...... and hepatocellular carcinoma.
@en
type
label
Nonsteroidal anti-inflammatory ...... and hepatocellular carcinoma.
@ast
Nonsteroidal anti-inflammatory ...... and hepatocellular carcinoma.
@en
prefLabel
Nonsteroidal anti-inflammatory ...... and hepatocellular carcinoma.
@ast
Nonsteroidal anti-inflammatory ...... and hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
Nonsteroidal anti-inflammatory ...... and hepatocellular carcinoma.
@en
P2093
Albert R Hollenbeck
Barry I Graubard
Britton Trabert
Katherine A McGlynn
Lauren M Schwartz
Munira Z Gunja
Neal D Freedman
Vikrant V Sahasrabuddhe
P2860
P304
P356
10.1093/JNCI/DJS452
P407
P50
P577
2012-11-28T00:00:00Z